Gossamer bio presented clinical and preclinical data at the pulmonary vascular research institute 2025 annual congress

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), presented one oral presentation and three posters related to seralutinib at the pulmonary vascular research institute (pvri) 2025 annual congress that took place january 29th through february.
GOSS Ratings Summary
GOSS Quant Ranking